Combination therapy of zongertinib and a kras g12c inhibitor against cancer

CL202601370A1Pending Publication Date: 2026-07-24BOEHRINGER INGELHEIM INT GMBH

View PDF 0 Cites 0 Cited by

Patent Information

Application Number: CL202601370
Authority / Receiving Office: CL · CL
Patent Type: Applications
Current Assignee / Owner
Priority Date: 2024-12-18
Filing Date: 2026-04-28
Publication Date: 2026-07-24

Application Information

Patent Timeline

18 Dec 2024

Priority

28 Apr 2026

Application

CL202601370

24 Jul 2026

Publication

CL202601370A1

IPC: A61K31/519; A61P35/00

CPC: A61K31/519; A61P35/00; A61K2300/00

Inventors: BAUM Anke; SAVARESE Fabio

Get more patent work done with AI

Run novelty searches—or use them for FTO, design risk, drafting and technical problem-solving.

Explore More Agents

Novelty Search
Search existing technologies and assess novelty
↗
FTO
Analyze whether a product may infringe others' patents
↗
Design FTO
Check prior-design risk for exterior design
↗
Drafting
Draft patent application text based on a technical solution
↗
Find Solutions with TRIZ
Generate feasible solution to solve your technical challenge
↗
IP MCP Servers
Connect trusted patent search and cited evidence to Claude, Cursor or your own AI workflow
↗

Patent Text Reader

Abstract

The present invention relates to the combination of the HER2 tyrosine kinase inhibitor zongertinib with a KRAS G12C inhibitor. The combination of the invention is useful for the treatment and / or prevention of oncological and / or hyperproliferative diseases, such as cancer. Therefore, the invention also provides compounds for uses, methods of prevention and / or treatment, pharmaceutical compositions, and kits related to the combination.

Need to check novelty before this filing date? Find Prior Art